What is BCDA's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.02B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for BCDA?

P/E (TTM) is n/a and 52-week range is $0.75 to $1.80 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s BCDA figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for BCDA?

The company profile lists revenue (TTM) near $431K, net income (TTM) near $-856M, EPS (TTM) near $-0.80 when available from the market-data feed. Figures are informational and may lag live markets.

Where is BioCardia Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Sunnyvale, California, US, 14.9M shares outstanding, ISIN US09060U6064 when available from company profile and filing metadata.

BioCardia Inc

$BCDA

Health Care · Biotechnology

IR Run Scenarios

$1.04

-1.89%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

BioCardia, Inc. is a clinical-stage biotherapeutic company, which engages in the business of developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. The company is headquartered in Sunnyvale, California and currently employs 17 full-time employees. The company is advancing two cell therapy platforms derived from bone marrow, such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia. Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome. Its CardiAMP autologous and CardiALLO allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph vascular navigation product platforms.

Employees

Website

www.biocardia.com/

IPO

1996-11-13

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)